Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
about
Bisphosphonates: mechanism of action and role in clinical practiceBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerCancer treatment-related bone disease.Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonatesBone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.FSH suppression does not affect bone turnover in eugonadal men.The best of both worlds - managing the cancer, saving the bone.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health and prostate cancer.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancerEffects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerManagement of complications of prostate cancer treatment.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerGonadal steroids and body composition, strength, and sexual function in menBone health in nonmetastatic prostate cancer: what's the big deal?Preventing bone complications in advanced prostate cancerCurrent management of castrate-resistant prostate cancer.Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.Medication-induced osteoporosis: screening and treatment strategiesEvaluation of degarelix in the management of prostate cancer.Treatment and prevention of bone complications from prostate cancer.Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Denosumab in men receiving androgen-deprivation therapy for prostate cancerMetastasis and bone loss: advancing treatment and prevention.Androgen deprivation therapy for prostate cancer: new concepts and concerns.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsTreatment-related osteoporosis in men with prostate cancer.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.NCCN Task Force Report: Bone Health in Cancer Care.Estrogenic side effects of androgen deprivation therapy.Update on medications with adverse skeletal effectsManagement of complications of androgen deprivation therapy in the older man.Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Intravenous bisphosphonates for postmenopausal osteoporosis.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksContemporary therapeutic approaches targeting bone complications in prostate cancer
P2860
Q24644708-7ABB1454-A8FE-4D7A-ABBD-497AE0AB970DQ27021268-406B2D4D-07BD-4400-89C9-6B2CB9D1042CQ30438185-C107671B-3147-4948-92A6-AFEE82FEE120Q33236626-E984A2A9-8813-43FC-B0BF-30DE93571AA8Q33553916-A9440DC9-814E-4C68-83F5-EA6F04F53841Q33754036-4ED003CF-0459-45E5-AE4B-06DF55397211Q33789201-CF7562D6-7610-4325-9278-97422C536888Q33837126-5BFDEB76-5A39-468D-A42A-8171F141D11BQ33920055-45D34CBB-53A4-421B-9BD5-37890A1549F5Q33977523-75B1C471-8E17-4C57-98D3-E003D5016C00Q33977536-52A0FD0B-4E25-4D4D-882C-061598F42514Q33977543-998E4469-1AC8-46E6-B018-E9E6D76738EFQ33978286-9B065C6A-F86B-48E5-94DE-B674427FECCAQ33978360-F77C2059-FA41-4020-952C-D6B3B13062CBQ34023510-FC589227-8BBF-4BD7-A13C-3797F019E18BQ34081897-B7DC4CF5-22DC-4CF7-9513-DE99DFE90A41Q34111621-C552D621-3BFE-4472-A4CF-459855DBC338Q34111634-05C9BFCB-BD9E-4013-B0DA-AA8A6FE2A493Q34111641-DD5AD086-9698-44D4-B008-697A0749F86DQ34339740-E4155A56-07CF-4E21-BE97-26FD8BD2D00FQ34389358-F698D71D-A900-41BF-B640-8C078C9F367FQ34417797-64E8DFE6-337B-4E7F-9FD0-5EA63D3A8623Q34441944-D43669ED-2DAF-4C4E-B5B3-A573232359BAQ34487137-921B50DD-A0E4-4060-9A64-1CCBAE8D85BBQ34497901-27E7E045-718A-4345-BCC2-3258FD95A06FQ34570396-D0D90BAA-CF6F-48A7-BA87-33F97F12B0B5Q34617837-F386FB55-0FA8-44AF-ABBC-25706F00D336Q34617845-59BE65AC-B8E3-42B7-A5A6-58D2B347FF63Q34617864-93762C8C-4258-4575-8A94-CDB4E8EFD774Q34617878-F9C213F0-D28C-44C9-BAD8-5E0E3D191364Q34617892-5E255A37-EB78-4797-84BC-7A842BC83FABQ34617931-879C1506-4610-4BDC-8920-A5888F3C760EQ34617936-B8BB4828-4224-440F-AE22-7626458A9DB8Q34743239-3915B4DA-F372-4FC0-9039-FB743FA0CF00Q34748485-49B985EE-808D-4B0E-B832-8C6EF4E1DCFAQ34782101-70DA1BF6-D0BB-4434-9B40-6BB0511CB155Q34823216-A3D67ACD-6148-48A6-A0E1-EA95D18162C0Q34863964-CCCC6715-A2A9-449F-974D-F7FB6BD66965Q34960686-07639EB1-7206-42E4-98C8-20D07EA050F0Q34960778-1AAAB82F-07AE-46C7-A0F8-C1437E8C434A
P2860
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@en
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@nl
type
label
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@en
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@nl
prefLabel
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@en
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@nl
P2093
P356
P1476
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
@en
P2093
Finkelstein JS
McGovern FJ
Schoenfeld DA
Zietman AL
P304
P356
10.1056/NEJMOA010845
P407
P577
2001-09-01T00:00:00Z